Compare KSCP & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | XLO |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 49.8M |
| IPO Year | 2022 | 2021 |
| Metric | KSCP | XLO |
|---|---|---|
| Price | $2.95 | $8.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $17.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 470.2K | 32.4K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $11,335,000.00 | ★ $43,766,000.00 |
| Revenue This Year | $218.66 | N/A |
| Revenue Next Year | $54.32 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.91 | ★ 589.88 |
| 52 Week Low | $2.52 | $0.46 |
| 52 Week High | $10.13 | $9.25 |
| Indicator | KSCP | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 57.52 |
| Support Level | $2.52 | $0.62 |
| Resistance Level | $4.50 | $9.03 |
| Average True Range (ATR) | 0.23 | 0.44 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 62.01 | 60.31 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.